Results 161 to 170 of about 1,144,383 (262)
Prior glucocorticoid exposure is associated with modestly increased vancomycin clearance in hospitalized children, partly mediated by renal function and inflammation and may contribute to subtherapeutic early drug exposure. Abstract Introduction Augmented renal clearance (ARC) can lead to subtherapeutic vancomycin exposure in children.
Kouki Tomari +6 more
wiley +1 more source
Metabolic Modulation of Type 2 Diabetes Mellitus by 1-Deoxynojirimycin: A Multifaceted Approach. [PDF]
Zhang Y +5 more
europepmc +1 more source
Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu +7 more
wiley +1 more source
Sarcopenia in type 2 diabetes mellitus: an imaging review. [PDF]
He L +10 more
europepmc +1 more source
Aim Pancreatic enzyme replacement therapy (PERT) is essential for the management of pancreatic exocrine insufficiency. Since June 2023, the United Kingdom has been affected by a global shortage of PERT. We investigated the impact of this shortage on national prescribing trends for Creon, Nutrizym, Pancrex and Pangrol.
Teena S. Varghese +6 more
wiley +1 more source
Association between TyHGB and hyperuricemia and gout in patients with type-2 diabetes mellitus. [PDF]
Zhang Q, Xu J, Qian Y.
europepmc +1 more source
Aims Clozapine is the most effective antipsychotic in treatment‐resistant schizophrenia. Clozapine causes weight gain and increased diabetes risk. The role of its metabolite norclozapine and clozapine:norclozapine ratio (CLZ/NCLZ) in metabolic effects has been debated.
Susanna Maria Rask +6 more
wiley +1 more source
Mapping research trends in shared decision-making for type 2 diabetes mellitus: a bibliometric study. [PDF]
Salgado-Castillo C +3 more
europepmc +1 more source
Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications
Dolutegravir underpins modern first‐ and second‐line HIV treatment regimens; however, interindividual variability in its disposition and tolerability presents challenges for optimal use. This scoping review mapped current evidence on the pharmacogenomics of dolutegravir, focusing on pharmacokinetics and pharmacodynamics, and methodological limitations ...
Ronald Kiguba +2 more
wiley +1 more source

